SCHEMBL7140692

SCHEMBL7140692

CCC(c1ccccc1)N(C)Cc1c[c]ccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.39
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
SLC6A3 Q01959 4/20 0.39
OPRK1 P41145 3/20 0.39
ADRA2B P18089 2/20 0.39
ADRA1A P35348 2/20 0.39
KCNH2 Q12809 2/20 0.39
ADRA2C P18825 1/20 0.39
TSHR P16473 4/20 0.35
ALDH1A1 P00352 1/20 0.35
HRH1 P35367 3/20 0.33
AOC3 Q16853 2/20 0.33
LMNA P02545 2/20 0.33
CCR5 P51681 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
MAOB P27338 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143569 0.77 USP2 (0.34) OPRK1ALDH1A1MEN1KMT2ACYP2D6
SCHEMBL6634552 0.77 ADRA2B (0.44) HTR2ASLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL2645309 0.75 ALDH1A1 (0.49) HTR2ASLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL28427943 0.73 ESR1 (0.42) ALDH1A1LMNACCR5TP53
SCHEMBL12126358 0.73 HTR2A (0.45) HTR2ASLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL1041217 0.73 TSHR (0.54) HTR2ASLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL7140660 0.72 CHRNB2 (0.50) TSHRALDH1A1LMNAMAOBCYP2D6
Water SCHEMBL27613449 0.70 HTR2A (0.46) HTR2ASLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL13452589 0.70 ADRA2B (0.50) HTR2ASLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL14017766 0.70 ADRA2B (0.50) HTR2ASLC6A2SLC6A4SLC6A3OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US claimed